Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors.


Journal

JAMA surgery
ISSN: 2168-6262
Titre abrégé: JAMA Surg
Pays: United States
ID NLM: 101589553

Informations de publication

Date de publication:
01 01 2019
Historique:
pubmed: 30 9 2018
medline: 26 11 2019
entrez: 30 9 2018
Statut: ppublish

Résumé

Neuroendocrine tumors (NETs) express somatostatin receptors, which can be targeted with radiolabeled peptides. In a variety of solid tumors, radioguided surgery (RGS) has been used to guide surgical resection. Gallium 68 (68Ga) dota peptides have been shown to be more accurate than other radioisotopes for detecting NETs. A pilot study previously demonstrated the feasibility and safety of 68Ga-dotatate RGS for patients with NETs. To evaluate what intraoperative techniques and thresholds define positive lesions that warrant resection during 68Ga-dotatate RGS. This prospective cohort study, conducted between October 23, 2013, and February 14, 2018, included 44 patients with NETs who underwent 68Ga-dotatate RGS. Gallium 68-dotatate RGS. The in vivo and ex vivo tumor to background ratio (TBR) was assessed for resected lesions and correlated with the histopathologic findings. Forty-four patients (22 women and 22 men; mean [SD] age, 51.0 [13.7] years) had 133 lesions detected on preoperative imaging scans, with a diagnosis of a pancreatic NET (19 of 44 [43%]), gastrointestinal NET (22 of 44 [50%]), and pheochromocytoma or paraganglioma (3 of 44 [7%]). The TBR was obtained by normalizing to the omentum (106 of 133 [79.7%]) or other solid organs (27 of 133 [20.3%]). The omentum had a significantly lower mean (SD) count than other solid organs for background count activity 3 hours after injection (22.1 [17.0] vs 34.5 [39.0]; P < .001). The lesions containing NETs had a higher TBR than those that did not contain NETs (18.9 vs 4.4; P < .001). On a receiver operating characteristic curve analysis, a TBR of 2.5 had a sensitivity of 90% and a specificity of 25%, and a TBR of 16 had a sensitivity of 54% and a specificity of 81%. A TBR of 2.5 or greater is a highly sensitive threshold for indicating a lesion to be consistent with a NET on histologic findings and thus warranting surgical resection. The omentum should be used as the background count activity for 68Ga-dotatate RGS for patients with abdominal NETs.

Identifiants

pubmed: 30267071
pii: 2702089
doi: 10.1001/jamasurg.2018.3475
pmc: PMC6439858
doi:

Substances chimiques

Organometallic Compounds 0
Radiopharmaceuticals 0
gallium Ga 68 dotatate 9L17Y0H71P

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-45

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

J Nucl Med. 2011 Nov;52(11):1679-83
pubmed: 21976529
J Clin Oncol. 2016 Feb 20;34(6):588-96
pubmed: 26712231
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S676-82
pubmed: 26350374
Nucl Med Rev Cent East Eur. 2017;20(1):49-56
pubmed: 28218348
Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):957-8
pubmed: 17431614
J Med Imaging Radiat Oncol. 2012 Feb;56(1):40-7
pubmed: 22339744
Q J Nucl Med Mol Imaging. 2017 Sep;61(3):247-270
pubmed: 28569457
World J Surg Oncol. 2009 Jan 27;7:11
pubmed: 19173715
J Nucl Med. 2016 Dec;57(12):1949-1956
pubmed: 27811124
J Surg Oncol. 2007 Sep 15;96(4):309-15
pubmed: 17726664
Neuroendocrinology. 2012;95(2):120-34
pubmed: 22261872
Acta Radiol. 2014 May;55(4):389-98
pubmed: 23928010
J Am Coll Surg. 2013 Sep;217(3):489-96
pubmed: 23891076
Nucl Med Commun. 2010 Dec;31(12):1025-32
pubmed: 20926978
Br J Surg. 2011 Nov;98(11):1617-24
pubmed: 21858790
Int J Surg. 2016 Apr;28 Suppl 1:S84-93
pubmed: 26721192

Auteurs

Mustapha El Lakis (M)

Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland.

Andreas Gianakou (A)

Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland.

Pavel Nockel (P)

Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland.

Douglas Wiseman (D)

Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland.

Amit Tirosh (A)

Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Martha A Quezado (MA)

Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland.

Dhaval Patel (D)

Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland.

Naris Nilubol (N)

Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland.

Karel Pacak (K)

Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.

Samira M Sadowski (SM)

Department of Thoracic and Endocrine Surgery, University Hospitals of Geneva, Geneva, Switzerland.

Electron Kebebew (E)

Department of Surgery, Stanford University, Stanford, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH